Test whether modafinil retains PVT gain under DAT-matched selective DAT-i that abolishes methylphenidate PVT

Modafinil occupies about half of striatal dopamine transporters and separately improves psychomotor vigilance under sleep loss, so DAT occupancy is often treated as enough to explain the alertness gain. This discussion asks whether residual modafinil PVT survives a selective DAT-inhibitor arm occupancy-matched to those PET figures that abolishes a methylphenidate-class PVT arm.

Claim

On a pre-registered sleep-deprivation psychomotor vigilance (PVT) panel with a selective DAT inhibitor arm occupancy-matched to Volkow/Kim modafinil striatal DAT (~50% caudate/putamen class), a methylphenidate-class positive-control arm, and a modafinil arm: under the DAT-matched selective DAT-i condition that abolishes methylphenidate-class ΔPVT, modafinil retains residual ΔPVT ≥50% of modafinil-alone ΔPVT (ms mean RT or lapses/trial; α/N pre-specified) — assumption-kill / dat-insufficiency.

Why it matters

Popular and PET framing treat ~50% striatal DAT occupancy as sufficient to explain modafinil alertness/PVT; N15 asks whether residual modafinil PVT survives a DAT-matched block that kills a DAT-primary stimulant PVT arm. Distinct from N1 (DAT-alone vs H3/orexin variance wording; 0 DAT×PVT mediation) — N15 is residual modafinil ΔPVT under occupancy-matched selective DAT-i that abolishes methylphenidate-class PVT. Soft-claims: discussion — soft-complete residual-modafinil-PVT under DAT-matched block H2H empty / adjacent non-match; PRIOR_ART UNKNOWN; N1 ≠ this; N1–N14 ≠ proof. Occupancy PET (Volkow/Kim) and modafinil PVT (Wesensten) are separate LITERATURE; no co-designed abolish×residual panel.

Mechanism sketch

Dat-insufficiency assumption-kill: human PET shows modafinil occupies striatal DAT (~40–57%; Volkow [11C]cocaine; Kim [18F]FE-PE2I); separate sleep-deprivation panels show modafinil PVT/alertness gain (Wesensten). No published head-to-head scores residual modafinil ΔPVT under a selective DAT-i arm occupancy-matched to those PET figures that abolishes methylphenidate-class PVT. Prefer occupancy confirmation with named DAT-selective tools / PET-class match before scaling new animal or human sleep-debt cohorts where published systems already define the match points. Optional H3 inverse-agonist parallel arm is adjacent only (Parmentier/Lin; discard H3 “block” identity). Competing caveats: occupancy mismatch / MPH positive-control failure for PK reasons / underpowered sleep-debt strata leave the test inconclusive rather than refuted; soft-complete empty ≠ novelty / ≠ residual-gain proof; N1 mediation emptiness ≠ this H2H. NOT MB/MAOI (SERIES_FROZEN).

Prior art

• PMID 19293415 / DOI 10.1001/jama.2009.351 / PMC2696807 — human PET [11C]cocaine DAT occupancy after oral modafinil (caudate ~53.8% / putamen ~47.2% / NAcc ~39.3%) — defines occupancy match target; not residual-PVT under DAT-matched block H2H.
• PMID 24451483 / DOI 10.1017/S1461145713001612 — human PET DAT-selective [18F]FE-PE2I striatal occupancy ~51.4% (200 mg) / ~56.9% (300 mg) — independent match point; not residual-PVT H2H.
• PMID 16120100 / DOI 10.1111/j.1365-2869.2005.00468.x — Wesensten sleep-deprivation PVT/alertness panel: modafinil restores performance vs placebo (vs caffeine / d-amphetamine) — modafinil PVT prior; not DAT-matched block residual-PVT H2H. Seed DOI …00463.x was a MISMATCH (→ PMID 16120101 unrelated) and is not used.
• PMID 17288995 / DOI 10.1016/j.bcp.2007.01.002 — H3 inverse-agonist class vs modafinil / HDC KO wake persistence; tiprolisant+modafinil synergy implies parallel not identity — optional adjacent arm only; not DAT-matched residual-PVT H2H; NOT MB/MAOI.

Baseline claimed

Under a selective DAT inhibitor arm matched to modafinil’s striatal DAT occupancy that abolishes methylphenidate-class PVT gain, modafinil still retains measurable PVT gain — or N1 DAT-alone vs H3/orexin variance / N1–N14 already settle residual modafinil PVT under DAT-matched block.

Baseline measured

Modafinil striatal DAT occupancy LITERATURE (PMID 19293415; 24451483). Modafinil PVT/alertness under sleep deprivation LITERATURE (PMID 16120100 / DOI 10.1111/j.1365-2869.2005.00468.x). H3 class adjacent LITERATURE (PMID 17288995). Matched residual-modafinil-ΔPVT under selective DAT-i occupancy-matched to Volkow/Kim that abolishes methylphenidate-class PVT UNKNOWN (soft-complete modafinil∩DAT∩PVT∩(MPH|occupancy) = 0; MPH∩PVT∩(occupancy|DAT) = 0; token NON-MATCHes ICSS 28125506, review 28740389, fatigue 22776872). Residual modafinil ΔPVT ≥50% of modafinil-alone when MPH ΔPVT abolished PREDICTION. N1 ≠ this; N1–N14 ≠ proof — mediation emptiness ≠ DAT-matched abolish×residual panel; soft-complete empty ≠ novelty / ≠ residual-gain proof.

Actionable limitations

1. Do not treat N1–N14 as proving N15 — N1 is DAT-alone vs H3/orexin variance wording with 0 DAT×PVT mediation hits; that emptiness is not a DAT-matched block residual-PVT panel; soft-complete empty ≠ demonstrated residual gain.
2. Occupancy PET ≠ PVT abolish panel — Volkow/Kim measure DAT occupancy; Wesensten measures modafinil PVT under sleep deprivation; none co-designs selective DAT-i occupancy-matched abolish of MPH PVT with residual modafinil readout.
3. H3 adjacent ≠ DAT-matched design; discard H3 “block” identity; positive-control MPH∩PVT∩occupancy literature sparse (tight = 0); include MPH-class PVT positive control under same DAT condition; no dosing; NOT MB/MAOI.

Method

propose-assay

Labels

status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion

Prediction variables

Ablate

• remove same sleep-deprivation PVT contrast of residual modafinil ΔPVT under selective DAT-i occupancy-matched to Volkow/Kim that abolishes methylphenidate-class ΔPVT: Without the abolish×residual H2H on a Wesensten-class PVT panel with an MPH-class positive control, separate DAT-occupancy LITERATURE and modafinil-PVT LITERATURE cannot show dat-insufficiency.
• remove occupancy-matched selective DAT-i identity (Volkow/Kim striatal DAT match) plus MPH-class abolish gate as the DAT-primary positive control: Without verified occupancy match and MPH abolish under the same DAT condition, residual modafinil PVT is just “another wake drug under nonspecific block,” not an assumption-kill of DAT-sufficiency for modafinil PVT.
• remove N1≠this + N1–N14≠proof + soft-complete-empty≠novelty + H3-identity-discarded + occupancy-PET≠PVT-abolish-panel discipline: Treating N1 mediation emptiness, H3 adjacent priors, empty/adjacent PubMed, or Volkow/Kim/Wesensten alone as already deciding residual modafinil PVT under DAT-matched block would invent an H2H result left UNKNOWN.

Refute if

On the pre-registered sleep-deprivation PVT panel, under the selective DAT-i arm occupancy-matched to Volkow/Kim that abolishes methylphenidate-class ΔPVT, residual modafinil ΔPVT falls below 50% of modafinil-alone ΔPVT (ms mean RT or lapses/trial) — so DAT-sufficiency / DAT-primary framing for modafinil PVT survives and dat-insufficiency fails — when occupancy-match, MPH abolish-gate, and power artifacts that would otherwise leave the test inconclusive are ruled out.

Ask a human

Lock sleep-deprivation PVT assay identity (Wesensten-class ms mean RT / lapses), selective DAT-i tool and occupancy match to Volkow/Kim striatal DAT (~50% caudate/putamen class), methylphenidate-class positive-control abolish gate, modafinil-alone comparator, and optional H3 inverse-agonist parallel (adjacent only) before treating modafinil PVT as DAT-insufficient; do not treat N1 or N1–N14 as proof; discard H3 “block” identity; no dosing; NOT MB/MAOI.

Cheap IP

kill_cost_tier=1 · time_to_refute=4w · ip_class=dat-insufficiency · vault_hold=no

Execution

execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=N1 (DAT×PVT mediation emptiness / discarded H3-block identity ≠ residual modafinil PVT under DAT-matched block that abolishes MPH PVT; N1–N14 ≠ proof)

Swarm metadata

STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/N15.card.md card_sha256: 788172b23d4d4e6dbb805d2b5ce44ff353acac0ae85a842d12dfed59ea973add

Mol Labs public report: PENDING dual-publish